Haematology and Oncology Flashcards
(110 cards)
What’s the pathophysiology underlying TTP?
ADAMST3 activity deficiency! Either acquired (95%) or genetic mutation (5%)
This protease normally breaks down ultra large polymers of vWF.
Failure to do so. = platelet clumping, micro-thrombi and red cell fragmentation.
What are the steps involved in primary haemostasis (platelet plug)?
1) Platelet adhesion to damaged vessel wall (GP1a-collagen) and GP1b-vWF)
2) Platelet activation via interaction with one another and with collagen and mediated by thrombin. Involves release of contents of alpha and dense granules.
3) Platelet aggregation (ADP released from dense granules binds to Platelet P2Y12 receptor activating the GPIIB/IIIa complex. The aggregation happens through the linking of platelet exposed GPIIB/IIIa complexes with fibrinogen and vWF
Describe the extrinsic pathway (initiation phase)
Extrinsic pathway involves TF on exposed tissue vessel wall after injury
TF binds FVII -> FVIIa
FVIIa binds FX -> FXa….
FXa interacts with cofactor FVa to activate prothrombin (FII) -> thrombin (FIIa)
Thrombin activates platelets, activates fibrinogen and also stimulates FV, FVIII and XIII
Describe the intrinsic pathway
Intrinsic pathway is activated by contact with -be charged surfaces (in Vivo by expose of subendothelial CT of damaged vessels).
Deficiencies of factors don’t usually cause bleeding
Process…
FXII interact with -ve charge surface -> FXIIa
FXIIa binds FXI -> FXIa
FXIa binds FIX -> FIXa
FIXa activates FX -> FXa
FXa enters common pathway
Describe the final common pathway of haemostasis
FXa activates FII (prothrombin) -> FIIa (thrombin)
This process involves cofactors FV, Calcium and happens on platelet surface.
FIIa (thrombin) hydrolyses FI (fibrinogen) -> FIa (fibrin)
Fibrin monomers aggregate
FIIa (Thrombin) activates FXIII -> FXIIIa
FXIIIa links (FXIa) fibrin polymers to form insoluble fibrin clot.
Describe Fibrinolysis
Fibrinolysis = process of breaking down fibrin and fibrinogen
Activators of fibrinolysis:
tPA - secreted by endothelial cells
Urokinase - released by macrophages
Factor XIIa ( intrinsic pathway)
Process:
tPA bind fibrin then activates plasmin from plasminogen.
Activated Plasmin then cleaves fibrin and fibrinogen to fibrin degredation products and D dimers.
NB. D dimers are specifically products of cross linked fibrin breakdown
Describe the processes involved in natural anticoagulation
1) Preventing platelet activation and aggregation
Endothelial cells secrete vasodilatory and anti platelet substances:
i) NO - inc cGMP - dec intracellular Ca -> vasodilation and inhibits platelet aggregation
ii) PGI2 - vasodilates. Prostacyclin also binds directly to platelet surface preventing their activation ( Gs GPCR)
2) Preventing fibrin clot formation
Tissue Factor inhibitor - expressed on the surface of the normal endothelium and inhibits extrinsic pathway
Antithrombin III - inhibits thrombin as well as intrinsic pathway factors -
Thromomodulin is a protein which modulates thrombin and this activates Protein C
(NB - thrombin also activates Protein C)
Protein C with the help of Protein S - inhibits cofactors V and VIII
3) Fibrinolysis
Process of plasmin breaking down fibrin and fibrinogen to FDP.
Plasminogen is activated to plasmin by 1) Urokinase, 2) tPA 3) Factor XIIa
PT test and causes of prolonged PT
PT (play tennis outside!)
- tests extrinsic pathway
- thromboplastin added to citrated blood
- time taken to clot measured
- normal 10-13 secs
- tests FI, II, VII, X
- INR = ratio of sample PT to international standard, warfarin therapy
Abnormal prolonged PT
- warfarin
- FII, FVII deficiency -> remember II/VII/IX and X need Vit K
- Vit K deficiency
- DIC
- Artefact - incorrect sampling or if Hct is high
APTT test and causes of abnormal result
Remember play table tennis inside!
- tests intrinsic pathway
- kaolin added to citrated blood
- tests factors XII, XI, IX, VIII and factors common to both pathways.
- Normally 30-35secs
Causes of prolonged APTT
- Heparin
- Haemophillia - A (factor VIII def)
- Haemophilia- B (factor IX def)
- Liver disease
- DIC
Mixing tests are performed in cases of prolonged APTT to determine if it is a true factor deficiency or there is an inhibitor present. (Mix sample with normal blood 50:50 - if APTT corrects it was a factor deficiency…if it remains prolonged do further tests for inhibitor…
Antiphospholipid syndrome causes prolonged APTT which doesn’t correct with mixing blood sample with 50:50 normal platelet free plasma
Adding heparinise, if heparin is present and causing prolonged APTT, the result will normalise when heparin activity is inhibited.
Describe the thrombin time and causes of abnormal result
- Thrombin is added to undiluted plasma
- common pathway assessment
- Tests time to conversion of fibrinogen FI -> fibrin FIa
Prolonged in:
- DIC
- heparin activity (inhibits thrombin by potentiating antithrombin )
- low fibrinogen levels
- direct thrombin inhibitor
Causes of an abnormal fibrinogen
High - acute phase protein
Low - sepsis and DIC
Describe classic features of TTP
FAT R/N
- Fever
- Anaemia
- Thrombocytopenia
-Renal problems ( more so HUS > TTP)
-Neuro problems ( TTP > HUS)
Principles of Mx of TTP
1) Replacement
- Plasma exchange
- FFP or cryo replacement ( has ADAMST13)
- 1.5 plasma volumes daily until plt > 150
2) Immune modulation
- Steroids - methylpred for 3 /7
- If neuro or cardiac involvement -> Rituximab ( monoclonal Ab which binds to CD20 on B cells to inhibit autoantibody production)
3) Can inhibit vWF with ? Caplacizumab
Why do coagulation mixing studies?
Mixing Studies help differentiate between factor deficiencies or factor inhibitors
If your sample of plasma is giving a high PT or aPTT - grab your suspicious plasma sample, and mix it with normal blood, 50:50. Obviously, if some sort of “factor inhibitor” is present, the normal blood will also be affected, and the resulting mixture will give abnormal aPTT and PT results. If there is a factor deficiency, the mixed sample will result in a normal PT or aPTT.
An abnormal mixing study result implies that in spite of the addition of normal plasma, the coagulopathy persists. This suggests that a factor inhibitor is present.
Go onto check antiphospholipid anticoagulant and heparin assay
What will prolong your PT and your APTT?
- DIC
- Massive transfusion
- Massive warfarin overdose
- Primary fibrinolysis - e.g in trauma
- Post thrombolysis
- Snake bite - which can be pro or anti-coagulant
- Direct thrombin inhibitor toxicity - thrombin time should be prolonged in this case but reptilase time normal
Severe liver failure
List some of the common thrombophilia’s
Thrombophilia = predisposition to clotting!
- Antithrombin III deficiency ( inherited or acquired)
- Protein C deficiency ( normally inhibits FV + FVIII)
- Protein S deficiency (assists Protein C)
- Lupus anticoagulant
- Prothrombin gene mutation
- Factor V Leiden mutation
What are the causes of Antithrombin III deficiency
ATIII is a protein, it inhibits thrombin activity. ATIII also inhibits intrinsic pathway CF.
Deficiency may be:
- Hereditary or;
- Acquired (reduced production, inc. consumption or protein loss)
- Reduced production -> Liver disease
- Increased consumption -> DIC, ECMO / CRRT circuits
- Protein loss -> nephrotic syndrome, major blood loss, plasmapheresis where replacement fluid is albumin
How do you manage Antithrombin III deficiency ?
- AT III concentrate
- FFP if concentrate not available
NB if using heparin for VTE prophylaxis - may not work at all or demonstrate resistance if ATIII deficiency
What does the Thrombin time measure?
- Thrombin time measures conversion of Fibrinogen ( FI) -> fibrin ( F1a)
- Prolonged Thrombin Clotting Time ( TCT) seen in low fibrinogen levels, heparin use or the generation of fibrin degradation products
What is the Ecarin Clotting time test?
- Ecarin is a snake protease
- it activates prothrombin (FII) bypassing the intrinsic and extrinsic systems
- therefore insensitive to the most part of the clotting system (eg effects of heparin / warfarin or on cases of factor depletion)
- it IS a useful test for direct thrombin inhibitors
Advantages of TEG over fixed ratio massive transfusion
*patient specific POCT - guided transfusion
*reduce unnecessary products
*Teg detects fibrinolysis and
hyperfibrinolysis
*faster than traditional clotting profile
*can be used to demonstrate medical vs surgical cause of coagulopathy - I.e can exclude medical causes of bleeding in trauma patient
Define Tumour Lysis Syndrome
TLS is an oncological emergency resulting from massive turnover and lysis of tumour cells causing release of potassium, phosphate and nucleic acids (urate is product of metabolism) into the circulation. Hypocalcaemia is also seen.
Results in:
*High K
*High PO4
*High Urate
*Low Ca
List the risk factors associated with the development of TLS
Patient related RF:
- Lymphomas. esp Burkitts
- Leukaemia’s
- High burden of disease
-some solid tumours - e.g. breast, testes
-CKD
-Nephrotoxics
-Dehydration
-Gout
Treatment related RF:
- aggressive chemo
-specific agents e.g….
- R-CHOP - e.g. rituximab, cyclophosphamide, vincristine, doxorubicin, prednisilone
Principles of prevention of tumour lysis
*Anticipate
*Hydrate - enhance renal clearance of solutes and reduce r/o precipitation of urate crystals
*Frequent Electrolyte monitoring - K, Ca, Urate, PO4, UEC
Specific Rx:
*Allopurinol = xanthine oxidase inhibitor to reduce urate formation
*Rasburicase = recombinant urate oxidase, enhances degradation of urate to allatonin which is more soluble and excreted renally